What Is a GLP-1 Medication? A Plain-Language Explanation

If you've heard the term "GLP-1" but aren't sure what it actually does in your body, this breaks it down without the jargon.

GLP-1 medications work by copying a hormone your gut already makes after you eat. That hormone helps control blood sugar and appetite, but it doesn't stick around for long — GLP-1 drugs are built to keep that same signal active for hours or days instead of minutes, which is what produces the appetite and blood-sugar effects these medications are known for. This article walks through what GLP-1 actually is, how the medications work in your gut and brain, which drugs are currently FDA-approved for weight loss, and what the clinical trials found about how much weight people lose and how long it takes.

What GLP-1 Actually Is

GLP-1, short for glucagon-like peptide-1, is a natural hormone that belongs to a class called incretins — hormones released by the gut after you eat to help the body manage the sugar coming in from food. It's produced mainly by cells lining the small and large intestine, with a smaller amount made in the brain, and it's released into the bloodstream in response to carbohydrates and fats.

On its own, GLP-1 does several things at once: it prompts the pancreas to release insulin when blood sugar rises, it suppresses the hormone that tells the liver to release stored sugar, it slows down how quickly food leaves the stomach, and it reduces appetite. The problem is that natural GLP-1 gets broken down by an enzyme within minutes, so its effects don't last.

Why the Medications Last So Much Longer

GLP-1 receptor agonist medications are synthetic versions engineered to resist that fast breakdown. Instead of lasting minutes, they stay active in the body long enough to be dosed once daily or, in most cases, once weekly. The medication attaches to the same receptors the natural hormone uses, so the body responds as if GLP-1 were present continuously — which is what sustains the effects on appetite and blood sugar throughout the week.

How It Works in Your Gut and Brain

The Gut Effect

GLP-1 receptors sit throughout the nervous system that controls digestion. When a GLP-1 medication activates those receptors, the stomach empties more slowly and the valve leading to the small intestine tightens. Food stays in the stomach longer, which is the main reason people feel full after eating less than they used to — and it's also the leading cause of the nausea many people experience when starting treatment or increasing their dose.

The Brain Effect

GLP-1 receptors are also present in the parts of the brain that regulate hunger and fullness, including the hypothalamus and brainstem. Activating these receptors strengthens the "I'm full" signal and quiets the "I'm hungry" signal, which lowers overall food intake independent of what's happening in the stomach. This dual gut-and-brain action is a major reason GLP-1 medications tend to produce more weight loss than appetite-suppressant drugs that work through only one pathway.

What the Research Shows

In the pancreas, these medications increase insulin release only when blood sugar is already elevated, which lowers the risk of blood sugar dropping too low compared to some older diabetes medications. They also reduce the release of stored sugar from the liver. Combined, these two effects are why GLP-1 drugs were originally developed for type 2 diabetes before their weight-loss effects led to dedicated obesity indications.

Which GLP-1 Medications Are FDA-Approved for Weight Loss

Three medications currently carry FDA approval specifically for chronic weight management in adults with obesity or overweight plus a weight-related health condition:

• Wegovy (semaglutide) — a once-weekly injection and a GLP-1-only medication.
• Zepbound (tirzepatide)— a once-weekly injection that activates both the GLP-1 receptor and a second hormone receptor called GIP, making it a "dual agonist."
• Foundayo (orforglipron)— a once-daily oral tablet, currently the only FDA-approved GLP-1 pill for weight loss. Chemically it's a small molecule rather than a peptide, which is what allows it to be taken orally, but it activates the same GLP-1 receptor as the injectable options.

The dual-agonist mechanism in tirzepatide is worth understanding: GIP is a second incretin hormone, and activating both receptors at once appears to produce an additive effect on insulin release, appetite, and weight loss compared to activating GLP-1 alone.

What the Clinical Trials Found

In the semaglutide trial (STEP-1), nearly 2,000 adults with obesity who did not have diabetes lost an average of 14.9% of their starting body weight over 68 weeks, alongside improvements in cardiometabolic risk factors.

In the tirzepatide trial (SURMOUNT-1), participants at the highest dose lost an average of up to 20.9% of body weight over 72 weeks, with more than half of participants losing at least 20% of their starting weight.

Foundayo's approval was based on two placebo-controlled trials over 72 weeks that found statistically significant and clinically meaningful weight loss compared to placebo, though head-to-head percentage comparisons with the injectable options weren't part of the approval trials.

How Long Results Take

None of these trials showed rapid, short-term results. Weight loss built gradually over the full trial period — 68 to 72 weeks — rather than plateauing early. These medications are designed and studied as long-term, ongoing treatments, not short courses, and the data on stopping treatment backs that up: people who discontinue a GLP-1 medication tend to regain most of the weight they lost, along with a rise in the cardiometabolic risk factors that had improved during treatment.

What This Means for You

Because these are long-term medications with real physiological effects on your gut, pancreas, and brain, they come with side effects and precautions worth understanding before starting one — not to alarm you, but so nothing catches you off guard.

The most common side effects across the class are gastrointestinal: nausea, vomiting, diarrhea, and constipation, most pronounced when starting treatment or increasing the dose. Foundayo's label also lists indigestion, abdominal pain and bloating, fatigue, reflux, gas, and hair loss as common effects.

When to Seek Care

Less common but more serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and — for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 — these medications are contraindicated due to thyroid tumor findings in animal studies. If you experience severe abdominal pain, persistent vomiting, signs of dehydration, or a lump in your neck while on a GLP-1 medication, contact a licensed healthcare provider promptly. Notably, in 2026 the FDA requested removal of the suicidal ideation and behavior warning from GLP-1 labeling after its safety evaluation found no increased risk — but any new or worsening mood changes are still worth discussing with your prescriber.

How Providers Typically Approach GLP-1 Treatment

Most telehealth providers offering GLP-1 medications follow a similar structure: an intake questionnaire, a clinician consultation (live video or asynchronous, depending on the provider), lab work in some cases, and ongoing dose titration managed remotely. Pricing, pharmacy type (brand-name versus compounded), and consultation format vary significantly between providers — details worth comparing before choosing one.

Frequently Asked Questions

Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →

Find providers worth comparing.

Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.